{"69700":{"#nid":"69700","#data":{"type":"event","title":"Distinguished Lecture: Nobel Laureate Aaron Ciechanover","body":[{"value":"\u003Cp\u003E\u201cDrug Development in the 21st Century: Are We Going to Cure all Diseases?\u201d\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003EAaron Ciechanover\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003ECancer and Vascular Biology Research Center, Faculty of Medicine\u003C\/p\u003E\u003Cp\u003ETechnion-Israel Institute of Technology\u003C\/p\u003E\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EDate: Tuesday, Oct. 4, 2011\u003C\/p\u003E\u003Cp\u003ETime: 6:30 p.m. (pre-lecture reception with refreshments begins at 6 p.m.)\u003C\/p\u003E\u003Cp\u003ELocation: Georgia Tech College of Management\u003C\/p\u003E\u003Cp\u003E800 West Peachtree Street NW\u003C\/p\u003E\u003Cp\u003EAtlanta, GA 30308\u003C\/p\u003E\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E\u003Cp\u003ENo charge to attend, but RSVPs are requested. \u003Cstrong\u003E\u003Ca href=\u0022http:\/\/www.surveymonkey.com\/s\/HW5GZZL\u0022\u003EClick here to RSVP.\u003C\/a\u003E\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003E\u003Ca href=\u0022http:\/\/mgt.gatech.edu\/about_us\/map_directions.html\u0022\u003EClick here for directions \u0026amp; parking information for the College of Management.\u003C\/a\u003E\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003E\u003Cbr \/\u003E\u003C\/strong\u003E\u003C\/p\u003E\u003Ch5\u003E\u003Cstrong\u003EAbstract\u003C\/strong\u003E\u003C\/h5\u003E\u003Cp\u003EMany important drugs such as penicillin, aspirin or digitalis, were discovered by serendipity - some by curious researchers who accidentally noted a \u0022strange\u0022 phenomenon, and some by isolation of active ingredients form plants known for centuries to have a specific therapeutic effect. Other major drugs like statins were discovered using more advanced technologies, such as targeted screening of large chemical libraries. In all these cases, the mechanisms of action of the drug were largely unknown at the time of their discovery, and were unraveled only later. With the realization that patients with apparently similar diseases at diagnosis \u2013 breast or prostate cancer, for example - respond differently to treatment, and the clinical behavior of the\u0026nbsp; disease is different in different patients, we have begun to understand that the molecular basis of what we thought is the same disease entity, is different. Thus, breast cancer or prostate cancer appear to be sub-divided to smaller classes according to their molecular characteristics.\u0026nbsp; As a result, we are exiting the era where our approach to treatment of these and many other diseases is \u201cone size fits all\u201d, and enter a new one of \u201cpersonalized medicine\u201d where we shall tailor the treatment according to the patient\u2019s molecular\/mutational profile.\u0026nbsp; Here, unlike the previous era, the understanding of the mechanism will drive the development of the new drugs. This era will be characterized initially the development of technologies where sequencing and data processing of individual genomes will be fast (few hours) and cheap (\u0026lt;US$ 1,000), by identification and characterization of new disease-specific molecular markers and drug targets, and by design of novel, mechanism-based drugs to modulate the activities of these targets. It will require a change in our approach to scientific research and development and to education, where interdisciplinarity will domineer and replace in many ways the traditional, discipline- oriented approach. Entry into this era will be also accompanied by complicated bioethical problems, where detailed genetic information of large populations in developed countries will be now available, and protection of privacy will become a major problem to health authorities.\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp; \u003C\/p\u003E\u003Ch5\u003E\u003Cstrong\u003ESpeaker Bio\u003C\/strong\u003E\u003C\/h5\u003E\u003Cp\u003EA native of Haifa, Professor Ciechanover received his Master of Science in 1970 and his M.D. in 1975 from the Hadassah Medical School of the Hebrew University in Jerusalem.\u0026nbsp; He received his doctorate in medicine in 1981 from the Technion, and has been a Distinguished Research Professor at the Center for Cancer and Vascular Biology and the Director of the Rappaport Family Institute for Research in Medical Sciences at the Technion.\u0026nbsp; \u003C\/p\u003E\u003Cp\u003EIn 2004, he shared the Nobel Prize for Chemistry with Professor Avram Hershko and Professor Irwin Rose for the discovery of ubiquitin-mediated protein degradation, a mechanism by which the cells of most living organisms cull unwanted proteins. Besides being awarded the Nobel Prize, Professor Ciechanover shared the pretigious Albert Lasker Award for Basic Medical Research, the second most prestigious prize in life sciences and medicine, and the Israel Prize, the highest recognition bestowed by the State of Israel.\u0026nbsp; Among many esteemed bodies, he is a member of the Israeli National Academy of Sciences and Humanities, the Pontifical Academy of Sciences of the Vatican and the American Philosophical Society.\u003C\/p\u003E","summary":null,"format":"limited_html"}],"field_subtitle":"","field_summary":"","field_summary_sentence":[{"value":"Ciechanover will speak about, \u201cDrug Development in the 21st Century: Are We Going to Cure all Diseases?\u201d"}],"uid":"27174","created_gmt":"2011-08-30 14:48:31","changed_gmt":"2016-10-08 01:55:34","author":"Mike Terrazas","boilerplate_text":"","field_publication":"","field_article_url":"","field_event_time":{"event_time_start":"2011-10-04T19:30:00-04:00","event_time_end":"2011-10-04T22:00:00-04:00","event_time_end_last":"2011-10-04T22:00:00-04:00","gmt_time_start":"2011-10-04 23:30:00","gmt_time_end":"2011-10-05 02:00:00","gmt_time_end_last":"2011-10-05 02:00:00","rrule":null,"timezone":"America\/New_York"},"extras":[],"hg_media":{"69886":{"id":"69886","type":"image","title":"Ciechanover Lecture","body":null,"created":"1449177275","gmt_created":"2015-12-03 21:14:35","changed":"1475894611","gmt_changed":"2016-10-08 02:43:31","alt":"Ciechanover Lecture","file":{"fid":"192857","name":"ciechanover-eblast.jpg","image_path":"\/sites\/default\/files\/images\/ciechanover-eblast_0.jpg","image_full_path":"http:\/\/www.tlwarc.hg.gatech.edu\/\/sites\/default\/files\/images\/ciechanover-eblast_0.jpg","mime":"image\/jpeg","size":65366,"path_740":"http:\/\/www.tlwarc.hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/images\/ciechanover-eblast_0.jpg?itok=P-IOTWVY"}}},"media_ids":["69886"],"groups":[{"id":"47223","name":"College of Computing"},{"id":"50875","name":"School of Computer Science"},{"id":"50876","name":"School of Interactive Computing"},{"id":"50877","name":"School of Computational Science and Engineering"}],"categories":[],"keywords":[{"id":"14160","name":"aaron ciechanover"},{"id":"2777","name":"drug development"},{"id":"7715","name":"Nobel Prize"}],"core_research_areas":[],"news_room_topics":[],"event_categories":[],"invited_audience":[],"affiliations":[],"classification":[],"areas_of_expertise":[],"news_and_recent_appearances":[],"phone":[],"contact":[],"email":[],"slides":[],"orientation":[],"userdata":""}}}